Morning Overview on MSN

A bispecific antibody beat a standard immunotherapy regimen head-to-head in squamous lung cancer at ASCO 2026

A bispecific antibody that simultaneously targets PD-1 and VEGF extended overall survival by more than four months compared ...
News Medical

Study reveals key mechanism of PD-1 function

Insights into the workings of an immune cell surface receptor, called PD-1, reveal how treatments that restrict its action can potentially be strengthened to improve their anticancer effect, a new ...
Fierce Pharma

ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%

It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. | ...
Labroots

Mass Photometry sheds light on the binding mechanism of the bispecific tetravalent anti-VEGF-PD-1 antibody Ivonescimab

Ivonescimab is a next-generation bispecific antibody that simultaneously targets programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF), two key molecules in the tumour ...
ascopubs.org

Use of causal modeling to uncover cell-cell communication dynamics in the tumor microenvironment during anti-PD-1 therapy in breast cancer patients.

Treatment with programmed cell death 1/programmed cell death ligand 1 inhibitors for Kaposi sarcoma: A systematic review and meta-analysis. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
ascopubs.org

Updated efficacy results of ASKB589 combined with CAPOX and PD-1 inhibitor as first-line treatment for metastatic gastric/gastro-esophageal junction (G/GEJ) adenocarcinoma from ...

Non-metastatic gastric cancer (GC) in patients aged 80 years or older: Immediate and long-term outcomes of combined treatment. Individual patient data (IPD) pooled analysis on the optimal therapeutic ...